Avivagen Inc. (VIV:TSX.V) announced in a news release it received governmental permission to sell OxC-beta Livestock in Mexico for broiler hens and pigs.
Specifically, the Secretaría de Agricultura y Desarrollo Rural associated with the Mexican General Office for Animal Health, Office of Livestock Services and Certification gave the approval.
It demonstrates the increasing validation of Avivagen's proprietary product and allows the company to sell it in a second, sizable North American market.
To expedite sales in Mexico, Avivagen will collaborate with Meyenberg International Group, a well-established and experienced marketing consulting firm in Guadalajara.
The release highlighted that Mexico's broiler hen and pig market consumes about 16 million tons of feed per year, roughly half of the 35 million tons consumed there in total. This makes Mexico the sixth largest feed consumer in the world, behind China, the U.S., Brazil, Russia and India.
"With our joint venture partnership already established in the U.S. with CSA Animal Nutrition and numerous confirmatory trials currently under way with large potential U.S. customers, we are very excited about the future growth of our company," Avivagen CEO Kym Anthony said in the release.
Avivagen is a "life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that, by safely supporting immune function, promote general health and performance."
Read what other experts are saying about:
Disclosure:
1) Doresa Banning compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. She or members of her household own securities of the following companies mentioned in the article: None. She or members of her household are paid by the following companies mentioned in this article: None.
2) The following company mentioned in this article is a billboard sponsor of Streetwise Reports: Avivagen. Click here for important disclosures about sponsor fees. As of the date of this article, an affiliate of Streetwise Reports has a consulting relationship with Avivagen. Please click here for more information.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article until three business days after the publication of the interview or article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases. As of the date of this article, officers and/or employees of Streetwise Reports LLC (including members of their household) own securities of Avivagen, a company mentioned in this article.
